Global status of antimicrobial resistance among environmental isolates of Vibrio cholerae O1/O139: a systematic review and meta-analysis

Yuan, Xin-hui; Li, Yu-mei; Vaziri, Ali Zaman; Kaviar, Vahab Hassan; Jin, Yang; Jin, Yu; Maleki, Abbas; Omidi, Nazanin; Kouhsari, Ebrahim

doi:10.1186/s13756-022-01100-3

Antimicrobial Resistance & Infection Control

Table 1 Prevalence of antibiotic-resistant in V. cholerae isolates from environmental samples based on years, quality, and continents

From: Global status of antimicrobial resistance among environmental isolates of Vibrio cholerae O1/O139: a systematic review and meta-analysis

Study	Effect Size				Heterogeneity				Test of ES = 0
Study	Proportion	LCI	HCI	% Weight	chi²	df	p	I²	z	p	Between sub-groups	Egger
Amoxicillin	0.68	0.31	0.96	100	25.55	2	0	92.17	4.65	0		0.622
2011–2020	0.58	0.45	0.71	66.45		1			11.7	0
2001–2010	0.81	0.64	0.93	33.55		0			11.67	0
HQ	0.58	0.45	0.71	66.45		0			11.7	0
LQ	0.81	0.64	0.93	33.55		1			11.67	0
Ciprofloxacin	0	0	0	100	15.29	14	0.36	8.41	0	1		0.465
2011–2020	0	0	0	65.8	2.22	8	0.97	0	0	1	0.03
2001–2010	0.02	0	0.07	34.2	7.15	5	0.21	0.3009	1.42	0.16
Africa	0	0	0.03	45.87	7.27	6	0.3	0.1742	0.88	0.38	0.67
Asia	0	0	0.03	35.01	5.49	4	0.24	0.2716	0	1
America	0	0	0.02	19.11		2		.%	0	1
HQ	0	0	0	91.48	14.01	13	0.37	0.0722	0	0.16	0.3
LQ	0.03	0	0.16	8.52		0		.%	1.42	1
Erythromycin	0.28	0.04	0.6	100	24.64	4	0	83.77	2.75	0.01		0.546
2011–2020	0.2	0	0.64	76.92	20.46	3	0	0.8534	1.62	0.1	0.21
2001–2010	0.5	0.32	0.68	23.08		0		%	7.96	0
Africa	0.44	0.07	0.84	60.05		2		%	2.84	0	0.14
Asia	0.12	0.01	0.28	39.95		1		%	2.6	0.01
HQ	0.2	0	0.64	76.92	20.46	3	0	0.8534	1.62	0.10	0.21
LQ	0.5	0.32	0.68	23.08		0		%	7.96	0
Furazolidone	0.62	0.2	0.96	100	187.93	6	0	96.81	3.65	0		0.894
2011–2021	0.69	0.59	0.79	29.5		1		%	16.62	0	0.69
2001–2011	0.6	0.13	0.98	70.5	83.94	4	0	0.9523	3.04	0
Africa	0.77	0.14	1	44.17		2		%	2.88	0	0
Asia	0.97	0.78	1	26.98		1		%	8.86	0
America	0.16	0.07	0.27	28.85		1		%	4.71	0
HQ	0.55	0.1	0.96	85.34	163.58	5	0	0.9694	13.75	0	0.07
LQ	0.94	0.79	0.99	14.66		0		%	2.9	0
Tetracycline	0.14	0.03	0.29	100	91.39	11	0.00	87.96	3.24	0.00		0.467
2011–2021	0.14	0.01	0.36	74.17	87.55	8	0.00	90.86	2.40	0.02
2001–2011	0.13	0.03	0.26	25.83	91.39	2	0.00		3.47	0.02
Asia	0.04	0.00	0.21	23.44		2			1.11	0.27	0.50
Africa	0.22	0.02	0.53	51.16	79.22	5	0.00	93.69	2.49	0.01
America	0.11	0.00	0.30	25.40		2			2.14	0.03
HQ	0.14	0.03	0.29	100	91.39	11	0.00	87.96	3.24	0.00
Doxycycline	0.05	0	0.14	100	22.93	6	0	73.83	1.95	0.05		0.577
2011–2021	0.03	0	0.1	72.35	8.69	4	0.07	0.5397	1.56	0.12	0.02
2001–2011	0.17	0.07	0.3	27.65		1		%	4.43	0
Africa	0.07	0	0.21	74.76	20.02	4	0	0.8002	2.11	0.03	0.18
America	0	0	0.07	25.24		1		%	0	1
HQ	0.28	0.14	0.47	15.81	8.9	5	0.11	0.4382	1.55	0.12	0
LQ	0.02	0	0.08	84.19		0		%	5.46	0
Chloramphenicol	0.12	0.01	0.29	100	114.33	9	0	91.25	2.63	0.01		0.401
2011–2022	0.03	0	0.11	54.31	11.52	5	0.04	0.5661	1.96	0.05	0.16
2001–2012	0.27	0	0.71	45.69	88.58	4	0	0.9548	2.07	0.04
Africa	0.11	0.01	0.25	64.21		0		%	2.77	0.01	0
Asia	1	0.74	1	8.56	37.47	6	0	0.8399	9.12	0
America	0	0	0.02	27.23		2		%	0	1
HQ	0.09	0	0.25	90.47	88.87	9	0	0.8987	2.23	0	0
LQ	0.47	0.29	0.65	9.53		0		.%	7.61	0.03
Nalidixic acid	0.37	0.09	0.7	100	256.8	11	0	95.72	3.34	0		0.527
2011–2022	0.49	0.05	0.94	58.09	189.52	6	0	0.9683	2.54	0.01	0.29
2001–2012	0.19	0.02	0.45	41.91	28.49	4	0	0.8596	2.54	0.01
Africa	0.4	0	0.91	34.4	119.93	3	0	0.975	2.04	0.04
Asia	0.35	0.01	0.81	40.08	37	4	0	0.8919	2.14	0.03
America	0.37	0	1	25.52		2		%	1.24	0.21
HQ	0.39	0.08	0.75	91.33		0		%	3.07	0	0.25
LQ	0.19	0.07	0.36	8.67	254.79	10	0	0.9608	4.24	0
Cotrimoxazole	0.59	0.3	0.85	100	306.32	14	0	95.43	5.29	0		0.74
2011–2023	0.66	0.3	0.95	52.97	120.59	7	0	0.942	4.55	0
2001–2013	0.51	0.11	0.89	47.03	143.9	6	0	0.9583	3.16	0
Africa	0.66	0.29	0.95	40.84	103.23	5	0	0.9516	4.49	0	0.84
Asia	0.63	0.21	0.97	38.72	51.84	5	0	0.9035	3.65	0
America	0.37	0	1	20.45		2		.%	1.24	0
HQ	0.56	0.26	0.84	93.04	281.9	13	0	0.9539	13.14	0	0.02
LQ	0.91	0.75	0.98	6.96		0		.%	4.8	0
Ampicillin	0.43	0.19	0.7	100	328.8	12	0	96.05	4.62	0		0.096
2011–2023	0.39	0.06	0.77	57.08	251.54	7	0	0.9722	2.87	0	0.67
2001–2013	0.5	0.2	0.79	42.92	52.37	5	0	0.9045	4.37	0
Africa	0.52	0.24	0.8	35.86	42.31	4	0	0.9054	4.74	0
Asia	0.51	0.03	0.98	42.51	220.15	5	0	0.9773	2.3	0.02
America	0.17	0	0.58	21.63		2		%	1.62	0.11
HQ	0.49	0.28	0.71	92.41	143.09	12	0	0.9161	6.14	0	0
LQ	0.01	0	0.04	7.59		0		%	1.42	0.16
Streptomycin	0.6	0.28	0.89	100	208.43	10	0	95.2	4.7	0		0.995
2011–2024	0.57	0.09	0.98	54.61	150.05	5	0	0.9667	2.81	0	0.84
2001–2014	0.64	0.21	0.97	45.39	56.94	4	0	0.9298	3.7	0
Africa	0.42	0	1	28.64		2		%	1.48	0.14	0.76
Asia	0.74	0.35	1	52.68	40.84	5	0	0.8776	4.53	0
America	0.62	0.48	0.75	18.68		1		%	11.63	0
Gentamicin	0	0	0	100	4.57	7	0.71	0	0	1		0.645
Ofloxacin	0	0	0.01	100	0.38	3	0.95	0	0	1
Ceftriaxone	0.02	0	0.12	100	29.21	5	0	82.88	1.15	0.25		0.489
2011–2024	0	0	0	64.13	0.99	3	0.8	0	0	1	0
2001–2014	0.16	0.08	0.26	35.87		1		%	5.61	0
Africa	0.04	0	0.1	36		1			2.24	0.03	0
Asia	0	0	0	45.19		2			0	1
America	0.14	0.05	0.29	18.8		0			4.21	0
HQ	0.04	0	0.16	78.95	15.36	4	0	0.7395	1.48	0.14	0.03
LQ	0	0	0.03	21.05		0		%	0	1
Kanamycin	0.05	0	0.2	100	4.27	2	0.12	53.11	1.48	0.14		0.967
Norfloxacin	0	0	0.03	100	2.69	3	0.44	0	0	1		0.795
Cefotaxime	0	0	0.05	100	2.89	2	0.24	30.86	0.44	0.66		0.549
Amikacin	0.2	0	0.69	100	20.85	2	0	90.41	1.41	0.16		0.81

Back to article page

ISSN: 2047-2994

Contact us

General enquiries: journalsubmissions@springernature.com